Verastem, Inc. (NASDAQ:VSTM – Get Free Report) was down 7.8% on Wednesday. The stock traded as low as $6.78 and last traded at $6.83. 1,021,681 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 2,585,704 shares. The stock had previously closed at $7.41.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on VSTM shares. Guggenheim set a $12.00 target price on Verastem and gave the stock a “buy” rating in a report on Friday, August 7th. BTIG Research boosted their price target on Verastem from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, October 15th. Wolfe Research initiated coverage on shares of Verastem in a research report on Thursday, September 17th. They set an “outperform” rating for the company. Mizuho increased their price objective on shares of Verastem from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, October 16th. Finally, HC Wainwright increased their price objective on shares of Verastem from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Verastem has an average rating of “Moderate Buy” and an average target price of $16.83.
View Our Latest Report on Verastem
Verastem Stock Down 7.2%
The firm has a 50 day simple moving average of $8.46 and a two-hundred day simple moving average of $6.31. The stock has a market capitalization of $866.32 million, a P/E ratio of -3.34 and a beta of 0.45. The company has a quick ratio of 1.91, a current ratio of 1.93 and a debt-to-equity ratio of 11.19.
Verastem (NASDAQ:VSTM – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.27). Verastem had a negative net margin of 178.38% and a negative return on equity of 359.49%. The business had revenue of $24.01 million during the quarter, compared to the consensus estimate of $26.57 million. On average, equities research analysts expect that Verastem, Inc. will post -1.72 earnings per share for the current year.
Insider Transactions at Verastem
In other Verastem news, CEO Dan Paterson sold 44,121 shares of Verastem stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $8.00, for a total value of $352,968.00. Following the transaction, the chief executive officer owned 652,712 shares in the company, valued at $5,221,696. The trade was a 6.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 48,041 shares of company stock valued at $386,390 in the last quarter. Insiders own 1.94% of the company’s stock.
Institutional Investors Weigh In On Verastem
Hedge funds have recently made changes to their positions in the stock. Opaleye Management Inc. acquired a new position in shares of Verastem during the second quarter worth $6,876,000. Exome Asset Management LLC lifted its stake in shares of Verastem by 58.5% in the 1st quarter. Exome Asset Management LLC now owns 636,700 shares of the biopharmaceutical company’s stock valued at $3,375,000 after acquiring an additional 234,957 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Verastem by 157.2% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 569,195 shares of the biopharmaceutical company’s stock valued at $2,174,000 after acquiring an additional 347,872 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Verastem by 31.6% during the 1st quarter. Bank of America Corp DE now owns 416,985 shares of the biopharmaceutical company’s stock valued at $2,210,000 after acquiring an additional 100,123 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Verastem during the 2nd quarter valued at $706,000. 88.37% of the stock is currently owned by institutional investors and hedge funds.
Verastem Company Profile
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.
Read More
- Five stocks we like better than Verastem
- SpaceX’s Wild Ride Puts 2 Space Stocks and a Weekly-Payout ETF in Focus
- Palantir’s Political Controversy Is Hiding a Much Bigger Story
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.
